Your session is about to expire
← Back to Search
Risankizumab for Psoriasis (LIMMITLESS Trial)
LIMMITLESS Trial Summary
This trial will test the safety and effectiveness of a new psoriasis drug over a long period of time.
LIMMITLESS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 18 Patients • NCT03022045LIMMITLESS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have any other ongoing or past health conditions, surgeries, abnormal test results, or substance abuse issues that could affect your ability to follow the study requirements, put your safety at risk, or impact the accuracy of the study data.You have had a history of moderate to severe chronic plaque psoriasis and have already participated in a previous study.
- Group 1: Risankizumab
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How does risankizumab compare to other drugs in its class?
"Risankizumab was first studied in 2011 at Memorial Sloan Kettering Cancer Center. As of now, there have been a total of 99 completed trials testing the efficacy of risankizumab. Additionally, 29 clinical trials are still ongoing; many of which are being conducted out of Verona, New jersey."
Are participants still being enrolled in this experiment?
"This particular trial is no longer looking for new patients; however, if you are still interested in participating in a clinical study, there are currently 179 trials for psoriasis and 29 trials for risankizumab that are actively enrolling patients."
Are there study sites in close proximity to each other?
"There are 100 sites running this trial, Verona, Santa Ana, Clinton Township and 97 other locations. Patients should try to select the location nearest to them in order to reduce travel time if they participate."
How many patients are participating in this clinical trial?
"Unfortunately, this study is no longer recruiting patients. However, there are currently 179 other trials studying psoriasis and 29 trials investigating risankizumab that are still enrolling participants."
When can patients in the USA expect to have access to risankizumab?
"Risankizumab's safety is estimated to be a 3. This conclusion is based on the fact that risankizumab is currently in Phase 3 trials, which suggests that while there is evidence of efficacy, further testing for safety is needed."
Which medical condition is risankizumab primarily prescribed for?
"In addition to treating dental plaque, risankizumab can also be used for therapeutic interventions such as psoriasis management, skin disinfecting therapy, and alleviating symptoms associated with psoriatic arthritis."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger